top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance

Updated: Jul 3

01/07/2025



HanchorBio and Henlius signed a ~$200M licensing deal for HanchorBio's HCB101 (Ref)


  • HanchorBio and Shanghai Henlius Biotech signed an out-licensing agreement which granted Henlius the exclusive development and commercialization rights to HanchorBio's HCB101 (SIRPα-IgG4 Fc fusion protein) across Greater China (including Mainland China, Hong Kong, and Macau), key Southeast Asian countries, as well as all countries in the Middle East and North Africa (MENA)


  • Under the terms of the agreement, HanchorBio will receive an upfront payment of $10 million, with additional payments tied to development and regulatory milestones of up to $192 million

     

  • Henlius will also pay tiered royalties and assume full responsibility for development, manufacturing, and commercialization in the licensed territories


  • HanchorBio retains all rights outside the licensed regions



Merck KGaA completed the acquisition of SpringWorks Therapeutics (Ref) 


  • Merck KGaA has closed the acquisition of SpringWorks Therapeutics for an enterprise value of $3.4 billion, following regulatory clearances and the fulfillment of other customary closing conditions


    • The definitive agreement was announced in Apr'25 


  • The business combination will immediately contribute to Merck’s revenues and is expected to be accretive to the company’s earnings per share pre (EPS pre) by 2027


  • Shares in SpringWorks will no longer be traded on the Nasdaq, with Merck now being the sole owner of SpringWorks



July 1, 2025: Ziihera received conditional marketing authorization from the EC for HER2-positive BTC (Ref)


  • Jazz Pharmaceuticals announced that the EC granted conditional marketing authorization for zanidatamab (Ziihera; dual HER2-targeted bispecific antibody) monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+) biliary tract cancer previously treated with at least one prior line of systemic therapy


    • The decision is based on results from the Phase 2b HERIZON-BTC-01 trial in which a pre-specified subgroup analysis in patients with IHC 3+ tumors (n=62) showed that zanidatamab elicited a cORR of 51.6%, with a mDOR of 14.9 months and mOS of 18.1 months


  • Continued approval for this indication is contingent upon verification and description of clinical benefit in the ongoing Phase 3 HERIZON-BTC-302 trial of zanidatamab + SOC vs SOC alone in the first-line setting for HER2-positive BTC


Comments

bottom of page